The National Agency for Health Surveillance (Anvisa) approved new therapeutic indications for the drug Trodelvy (sacituzumab govitecana), used in the treatment of adult patients with triple-negative breast cancer (MCTN).
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Use of Trodelvy is to treat triple-negative breast cancer, more aggressive and with fewer therapeutic options The post Anvisa approves new treatments with medication for breast cancer apareceu primeiro em AMAZONAS CURUAL.
The National Health Surveillance Agency (Anvisa) approved new therapeutic indications for Trodelvy (sacituzumab govitecana), used in the treatment of adult patients with triple-negative breast cancer (MCTN).